Restasis Payors Defend Class Cert. Bid In Allergan Suit
A group of Restasis buyers on Friday defended class certification in their New York federal suit accusing Allergan of boosting profits by delaying a cheaper generic version of the dry-eye medication,...To view the full article, register now.
Already a subscriber? Click here to view full article